MedTrace Logo

Marker Assisted Selective ThErapy in Rare Cancers: Knowledge Database Establishing registrY Asia

NCT05217407 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2024-03-22

No results posted yet for this study

Summary

This is a registry study that aims to collect patients' data with advanced-stage rare cancer in Asia-Pacific region. Data includes clinical information, details of treatment, prognosis, pathological diagnosis and genetic biomarkers by next-generation sequencing.

The relationship between cancer types and prognosis, the effect of treatments, and the cancer type-specific incidence of genomic alterations will be investigated to discover more specific and effective treatment.

Conditions

  • Rare Malignant Neoplasm

Interventions

OTHER

Genomic sequence

Genomic sequence

Sponsors & Collaborators

  • National Cancer Center, Japan

    lead OTHER_GOV

Principal Investigators

  • Noboru Yamamoro, MD, PhD · National Cancer Center Hospital, Japan

  • Kan Yonemori, MD, PhD · National Cancer Center Hospital, Japan

  • Kenichi Nakamura, MD, PhD · National Cancer Center Hospital, Japan

  • Yuta Maruki, MD · National Cancer Center Hospital, Japan

  • Takuji Okusaka, MD, PhD · National Cancer Center Hospital, Japan

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-30
Primary Completion
2027-03-31
Completion
2030-03-31

Countries

  • Japan
  • Malaysia
  • Philippines
  • South Korea
  • Taiwan
  • Thailand
  • Vietnam

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05217407 on ClinicalTrials.gov